Please login to the form below

Not currently logged in
Email:
Password:

Bristol Myers-Squibb launch Best to Test

Bristol Myers-Squibb is sponsoring a new initiative to improve the level of chronic myeloid leukaemia monitoring
Bristol Myers-Squibb is sponsoring a new initiative to improve the level of chronic myeloid leukaemia (CML) monitoring on the back of results of a recent survey that indicate that doctors are not doing enough in this area.

While UK GPs came out top of the poll of 550 physicians and specialists across Europe, the results show that 47 per cent of the respondents are not carrying out regular monitoring for CML patients.

The Best to Test initiative will push forward a drive to change and improve the level and quality of CML monitoring and testing after the data from the survey suggested that better education and support is needed.

"Resistance and intolerance to treatments are real concerns for patients and their physicians and monitoring in the correct way is key to achieving the longest possible survival rates," said Tony Gavin, chief executive of Leukaemia CARE UK.

23rd June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics